Vitae Pharmaceuticals (VTAE) Misses Q3 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Vitae Pharmaceuticals (VTAE) Misses Q3 EPS by 12c

Vitae Pharmaceuticals (VTAE) Ends 3Q With Cash Available Through 2016; Piper Jaffray Raises Price Target to $18

November 6, 2015 11:26 AM EST

Piper Jaffray reiterated an Overweight rating on Vitae Pharmaceuticals (NASDAQ: VTAE), and raised the price target to $18.00 (from $16.00), following the company's 3Q earnings report. Vitae ended 3Q:15 with $69 million, sufficient to fund the company through 2016. Lead candidate VTP-43742, inhibiting the RORt/IL-17 pathway, is currently in a multiple ascending dose trial in both healthy... More